Search Result

Results for "

bile acid receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	G protein-coupled Bile Acid Receptor 1 (20) 5 alpha Reductase (1) 5-HT Receptor (1) Angiotensin-converting Enzyme (ACE) (2) Antibiotic (1) Autophagy (11) Bacterial (1) Cholecystokinin Receptor (2) Constitutive Androstane Receptor (1) Cytochrome P450 (3) Drug Intermediate (1) Endogenous Metabolite (27) Ephrin Receptor (1) FXR (20) Histamine Receptor (3) Integrin (1) Isotope-Labeled Compounds (7) Leukotriene Receptor (3) Liposome (1) LPL Receptor (2) Phosphatase (1) Reference Standards (8) TNF Receptor (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (5) Endocrinology (2) Infection (4) Inflammation/Immunology (8) Metabolic Disease (46) Neurological Disease (1)
Oligonucleotides:	Emulsifiers (1)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1 Amino acid Transporter Amino Acid Derivatives Amino Acid Decarboxylase Hydroxycarboxylic Acid Receptor (HCAR) Amino Acid Oxidase Free Fatty Acid Receptor Fatty Acid Synthase (FASN)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0593

Deoxycholic acid 10+ Cited Publications Cholanoic acid; Desoxycholic acid	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N0593A

Deoxycholic acid sodium salt 10+ Cited Publications Sodium deoxycholate	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-13771A

Ursodeoxycholic acid sodium 15+ Cited Publications Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Cancer
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-76847

Chenodeoxycholic Acid 15+ Cited Publications CDCA	FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847A

Chenodeoxycholic acid sodium 15+ Cited Publications CDCA sodium	FXR Autophagy Endogenous Metabolite	Metabolic Disease Cancer
Chenodeoxycholic acid sodium is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-B1734

16-Dehydropregnenolone acetate 16-DPA	FXR 5 alpha Reductase Cytochrome P450 Drug Intermediate	Cardiovascular Disease Cancer
16-Dehydropregnenolone acetate (16-DPA), a sterols compound, is an orally active 17α-hydroxylase and 5α-reductase inhibitor. 16-Dehydropregnenolone is also a potent bile acid receptor (BAR)/farnesoid X receptor (FXR) antagonist. 16-Dehydropregnenolone hypolipidemic and anticancer effects. 16-Dehydropregnenolone acetate (16-DPA) is the drug intermediate that can be used for synthesis of Dexamethasone (HY-14648) and related other steroidal pharmacophores .

HY-N0593B

Deoxycholic acid sodium hydrate Cholanoic acid sodium hydrate; Desoxycholic acid sodium hydrate	Endogenous Metabolite G protein-coupled Bile Acid Receptor 1	Metabolic Disease
Deoxycholic acid (cholanoic acid) sodium hydrate, a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N0593R

Deoxycholic acid (Standard) Cholanoic acid(Standard); Desoxycholic acid (Standard)	Reference Standards G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid (Standard) is the analytical standard of Deoxycholic acid. This product is intended for research and analytical applications. Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N0593AR

Deoxycholic acid sodium salt (Standard) Sodium deoxycholate (Standard)	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid sodium salt (Standard) is the analytical standard of Deoxycholic acid sodium salt. This product is intended for research and analytical applications. Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-13771S1

Ursodeoxycholic acid-13C Ursodeoxycholate-¹³C; Ursodiol-¹³C; UDCA-¹³C	Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Cancer
Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-107612

GPBAR-A	G protein-coupled Bile Acid Receptor 1	Metabolic Disease
GPBAR-A is a specific agonist of the bile acid receptor GPBAR1. GPBAR-A can be used for the research of diabetes mellitus .

HY-13771

Ursodeoxycholic acid 15+ Cited Publications Ursodeoxycholate; Ursodiol; UDCA	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-169849

EphA2 antagonist 1	Ephrin Receptor	Others
EphA2 antagonist 1 (4b) is a bile acid conjugate and an *ephrin type-A receptor* 2 (EPHA2)** inhibitor .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-156830

TGR5 Receptor Agonist 4	G protein-coupled Bile Acid Receptor 1	Metabolic Disease
TGR5 Receptor Agonist 4 is an agonist of Bile Acid Receptor (TGR5), with EC₅₀ for hTGR5 and mTGR5 of 2 nM and 3 nM, respectively. TGR5 Receptor Agonist 4 plays important roles in hypoglycemic and weight loss .

HY-76847S

Chenodeoxycholic Acid-d4 CDCA-d₄	FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid-d₄ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-A0190

Ceruletide Maximum Cited Publications 97 Publications Verification Caerulein; Cerulein; FI-6934	Cholecystokinin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

HY-158722

Caerulein acetate	Cholecystokinin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Caerulein acetate is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide acetate is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

HY-76847S3

Chenodeoxycholic acid-d5 CDCA-d₅	Isotope-Labeled Compounds FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic acid-d₅ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-121110

Fexarene	FXR	Metabolic Disease
Fexarene is a potent and selective nonsteroidal Farnesoid X Receptor (FXR) agonist with an EC₅₀ of 36 nM. Fexarene can be used in studies of cholesterol and bile acid metabolism .

HY-76847S2

Chenodeoxycholic acid-13C CDCA-¹³C	FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic acid- ¹³C is the ¹³C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847S1

Chenodeoxycholic Acid-d9 CDCA-d₉	FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid-d₉ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-113478S

Ursodeoxycholic acid-2,2,4,4-d4	Isotope-Labeled Compounds	Infection Metabolic Disease
Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-133890

Tauro-α-muricholic acid T-α-MCA	Endogenous Metabolite FXR	Cardiovascular Disease Others Metabolic Disease
Tauro-alpha-muricholic acid (T-alpha-MCA) is a bile acid that belongs to a class of compounds that are synthesized in the liver and play an important role in the digestive process. Tauro-α-muricholic acid activates Farni X receptors (FXR) which are involved in the regulation of bile acid synthesis, metabolism and transport. Tauro-alpha-muricholic acid can be used in the study of metabolic syndrome and cardiovascular disease .

HY-135221R

Cefcapene pivoxil hydrochloride (Standard)	Reference Standards Bacterial Antibiotic	Infection
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-114392

Gly-β-MCA 10+ Cited Publications	FXR Autophagy	Metabolic Disease
Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders .

HY-76847R

Chenodeoxycholic Acid (Standard) CDCA (Standard)	Reference Standards FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-122338

Fexarine	FXR	Metabolic Disease
Fexarine is a potent, non-steroidal and selective agonist of farnesoid X receptor (EC₅₀: 38 nM). Fexarine can be used for the research of diseases linked to cholesterol, bile acids .

HY-76847S4

Chenodeoxycholic acid-d2 CDCA-d₂	Isotope-Labeled Compounds Endogenous Metabolite FXR Autophagy	Metabolic Disease Cancer
Chenodeoxycholic acid-d₂ (CDCA-d₂) is deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N0593S1

Deoxycholic acid-d5	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid-d₅ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N0593S

Deoxycholic acid-d4	Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid-d₄ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N0593S2

Deoxycholic acid-d6 Cholanoic acid-d₆; Desoxycholic acid-d₆	Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid-d₆ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-W712932

Chenodeoxycholic Acid-d7 CDCA-d₇	Isotope-Labeled Compounds FXR Autophagy Endogenous Metabolite	Metabolic Disease
Chenodeoxycholic Acid-d₇ (CDCA-d₇) is the deuterium labeled Chenodeoxycholic Acid (HY-76847). Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N0593S3

Deoxycholic acid-13C Cholanoic acid-¹³C; Desoxycholic acid-¹³C	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid- ¹³C is the ¹³C-labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-156830A

(4′R)-TGR5 Receptor Agonist 4	G protein-coupled Bile Acid Receptor 1	Metabolic Disease
(4′R)-TGR5 Receptor Agonist 4 is the R enantiomer of TGR5 Receptor Agonist 4 (HY-156830). TGR5 Receptor Agonist 4 is an agonist of Bile Acid Receptor (TGR5), with EC₅₀ for hTGR5 and mTGR5 of 2 nM and 3 nM, respectively. TGR5 Receptor Agonist 4 plays important roles in hypoglycemic and weight loss .

HY-146453

TGR5 Receptor Agonist 3	G protein-coupled Bile Acid Receptor 1	Metabolic Disease
TGR5 Receptor Agonist 3 (Compound 19) is a soft-agent G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonist with reduced gallbladder-filling effects (favorable gallbladder safety), with EC50s of 16.4 and 209 nM for hTGR5 and mTGR5, respectively.

HY-106932

L-734217	Integrin	Cardiovascular Disease
L-734217 is an orally active and potent fibrinogen receptor antagonist and an antithrombotic agent. L-734217 is excreted largely by the renal route and partly into the bile in dogs. L-734217 is promising for research of thrombotic disorders .

HY-113259

7α-Hydroxy-4-cholesten-3-one	Endogenous Metabolite	Metabolic Disease
7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a *pregnane X receptor* (PXR)** agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-120396

LY 293284	5-HT Receptor	Neurological Disease
LY 293284 is a potent and selective 5-HT1A receptor agonist. LY 293284 results in a significant drop in core temperature and consumes more food in cholestasis rat induced by bile duct resection .

HY-173466

LT-188A	G protein-coupled Bile Acid Receptor 1	Metabolic Disease Inflammation/Immunology
LT-188A is a potent TGR5 agonist with an EC₅₀ of 23 μM. LT-188A decreases the levels of inflammatory mediators in macrophages .

HY-165155

CysLT1 receptor antagonist-1	Leukotriene Receptor	Inflammation/Immunology
CysLT1 receptor antagonist-1 (Compound 4) is an antagonist for *cysteinyl leukotriene receptor* 1 (CysLT1R) with an IC₅₀** of 3.9 μM. CysLT1 receptor antagonist-1 exhibits weak agonist activity against *G-protein-coupled bile* acid receptor 1 (GPBAR1*) with an efficact of 23% at 10 μM. CysLT1 receptor* antagonist-1 can be used for asthma and allergic diseases researchs .

HY-114392R

Gly-β-MCA (Standard)	Reference Standards FXR Autophagy	Metabolic Disease
Gly-β-MCA (Standard) is the analytical standard of Gly-β-MCA. This product is intended for research and analytical applications. Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders[1].

HY-B1557

Betazole 1 Publications Verification Ametazole	Histamine Receptor	Metabolic Disease
Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .

HY-B1557A

Betazole dihydrochloride Ametazole dihydrochloride	Histamine Receptor	Metabolic Disease
Betazole (Ametazole) dihydrochloride, a pyrazole analogue of histamine, is an orally active H2 receptor agonist. Betazole dihydrochloride induces gastric acid secretion, and causes an immediate and significant increase in common bile duct pressure. Betazole dihydrochloride has been used as a diagnostic agent known as histalog, for investigating gastric acid secretory capacity .

HY-113259S

7α-Hydroxy-4-cholesten-3-one-d7	Endogenous Metabolite	Metabolic Disease
7α-Hydroxy-4-cholesten-3-one-d₇ is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-168329

TGR5 agonist 7	G protein-coupled Bile Acid Receptor 1	Metabolic Disease
TGR5 agonist 7 (Compound 22-Na) is a gut-restricted, orally active agonist for *G protein-coupled bile* acid receptor TGR5 (GPBAR1 or GPR131) with an EC₅₀** < 1 μM. TGR5 agonist 7 exhibits blood glucose lowering effect in mouse model, and can be used in diabete research .

HY-113259R

7α-Hydroxy-4-cholesten-3-one (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
7α-Hydroxy-4-cholesten-3-one (Standard) is the analytical standard of 7α-Hydroxy-4-cholesten-3-one. This product is intended for research and analytical applications. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a *pregnane X receptor* (PXR)** agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-168784

LTD4 antagonist 2	Leukotriene Receptor	Metabolic Disease Inflammation/Immunology
LTD4 antagonist 2 (compound 6) is a leukotriene D4 (LTD4) antagonist with an IC₅₀ of 2.8 μM against cysteinyl leukotriene 1 receptor (CysLT1R). LTD4 antagonist 2 is also a G protein-coupled bile acid receptor 1 (GPBAR1) agonist and can be utilized in research related to colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases .

HY-B1557R

Betazole (Standard) Ametazole (Standard)	Reference Standards Histamine Receptor	Metabolic Disease
Betazole (Standard) is the analytical standard of Betazole. This product is intended for research and analytical applications. Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .

HY-100619A

BMS-986020 sodium 5+ Cited Publications AM152 sodium	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0593

Deoxycholic acid 10+ Cited Publications Cholanoic acid; Desoxycholic acid	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N0593A

Deoxycholic acid sodium salt 10+ Cited Publications Sodium deoxycholate	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-13771A

Ursodeoxycholic acid sodium 15+ Cited Publications Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Inflammation/Immunology Disease Research Fields Steroids	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-76847

Chenodeoxycholic Acid 15+ Cited Publications CDCA	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Source classification Disease markers Endogenous metabolite Disease Research Fields Steroids Cancer	FXR Endogenous Metabolite Autophagy
Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847A

Chenodeoxycholic acid sodium 15+ Cited Publications CDCA sodium	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Cancer	FXR Autophagy Endogenous Metabolite
Chenodeoxycholic acid sodium is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-13771

Ursodeoxycholic acid 15+ Cited Publications Ursodeoxycholate; Ursodiol; UDCA	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Source classification Disease markers Endogenous metabolite Disease Research Fields Steroids Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-A0190

Ceruletide Maximum Cited Publications 97 Publications Verification Caerulein; Cerulein; FI-6934	Cardiovascular Disease Alkaloids Structural Classification Animals Classification of Application Fields Source classification Disease Research Fields Endocrinology Indole Alkaloids	Cholecystokinin Receptor
Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .

HY-N0593R

Deoxycholic acid (Standard) Cholanoic acid(Standard); Desoxycholic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Reference Standards G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
Deoxycholic acid (Standard) is the analytical standard of Deoxycholic acid. This product is intended for research and analytical applications. Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N0593AR

Deoxycholic acid sodium salt (Standard) Sodium deoxycholate (Standard)	Structural Classification Microorganisms Source classification Endogenous metabolite Steroids	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
Deoxycholic acid sodium salt (Standard) is the analytical standard of Deoxycholic acid sodium salt. This product is intended for research and analytical applications. Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Source classification Disease markers Endogenous metabolite Steroids	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-133890

Tauro-α-muricholic acid T-α-MCA	Structural Classification Human Gut Microbiota Metabolites Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite FXR
Tauro-alpha-muricholic acid (T-alpha-MCA) is a bile acid that belongs to a class of compounds that are synthesized in the liver and play an important role in the digestive process. Tauro-α-muricholic acid activates Farni X receptors (FXR) which are involved in the regulation of bile acid synthesis, metabolism and transport. Tauro-alpha-muricholic acid can be used in the study of metabolic syndrome and cardiovascular disease .

HY-76847R

Chenodeoxycholic Acid (Standard) CDCA (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Source classification Disease markers Endogenous metabolite Disease Research Fields Steroids Cancer	Reference Standards FXR Endogenous Metabolite Autophagy
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-113259

7α-Hydroxy-4-cholesten-3-one	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a *pregnane X receptor* (PXR)** agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-113259R

7α-Hydroxy-4-cholesten-3-one (Standard)	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Reference Standards Endogenous Metabolite
7α-Hydroxy-4-cholesten-3-one (Standard) is the analytical standard of 7α-Hydroxy-4-cholesten-3-one. This product is intended for research and analytical applications. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a *pregnane X receptor* (PXR)** agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

Cat. No.	Compare	Product Name	Species	Source

HY-P704194

	GPBAR1 Protein, Human (Cell-Free, His) G-protein coupled receptor GPCR19; hGPCR19; Membrane-type receptor for bile acids; M-BAR; hBG37; BG37	Human	E. coli Cell-free

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-76847S

Chenodeoxycholic Acid-d4
Chenodeoxycholic Acid-d₄ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847S3

Chenodeoxycholic acid-d5
Chenodeoxycholic acid-d₅ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847S2

Chenodeoxycholic acid-13C
Chenodeoxycholic acid- ¹³C is the ¹³C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-113478S

Ursodeoxycholic acid-2,2,4,4-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-N0593S1

Deoxycholic acid-d5
Deoxycholic acid-d₅ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-N0593S

Deoxycholic acid-d4
Deoxycholic acid-d₄ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-13771S1

Ursodeoxycholic acid-13C

Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-76847S1

Chenodeoxycholic Acid-d9
Chenodeoxycholic Acid-d₉ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847S4

Chenodeoxycholic acid-d2
Chenodeoxycholic acid-d₂ (CDCA-d₂) is deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N0593S2

Deoxycholic acid-d6
Deoxycholic acid-d₆ is the deuterium labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-W712932

Chenodeoxycholic Acid-d7
Chenodeoxycholic Acid-d₇ (CDCA-d₇) is the deuterium labeled Chenodeoxycholic Acid (HY-76847). Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N0593S3

Deoxycholic acid-13C
Deoxycholic acid- ¹³C is the ¹³C-labeled Deoxycholic acid. Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

HY-113259S

7α-Hydroxy-4-cholesten-3-one-d7

7α-Hydroxy-4-cholesten-3-one-d₇ is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

Cat. No.	Product Name		Classification

HY-N0593A

Deoxycholic acid sodium salt 10+ Cited Publications Sodium deoxycholate		Emulsifiers
Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

bile acid receptor

Inhibitors & Agonists

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products